Antisense oligonucleic acid

Patent metadata

Field	Value
Publication number	US-11261440-B2
Application number	US-201816487762-A
Country	US
Kind code	B2
Filing date	Feb 20, 2018
Priority date	Feb 21, 2017
Publication date	Mar 1, 2022
Grant date	Mar 1, 2022

Abstract

The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2′,4′-bridged nucleic acids, 2′,4′-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2′,4′-non-bridged nucleic acid residue(s) is/are modified.

First claim

The invention claimed is:

1. An antisense oligonucleic acid having a base length of not less than 7 nt and not more than 30 nt, wherein
nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from both terminals are 2′,4′-bridged nucleic acids,
2′,4′-non-bridged nucleic acid residue(s) is(are) present between both terminals, and
one or more bases in the nucleic acid residue(s) of the 2′,4′-non-bridged nucleic acid residue(s) is/are modified, wherein the one or more modified bases is 7-deaza-7-(2-phenylethynyl)guanine, 7-deaza-7-[2-(4-pyridyl)ethynyl]guanine, 7-deaza-7-[2-(2-pyridyl)ethynyl]guanine, 7-deaza-7-[2-(3-pyridyl)ethynyl]guanine, 7-deaza-7-[2-(C 1-7 alkanoyloxy-C 1-6 alkyl)ethynyl]guanine, 7-deaza-7-[2-(hydroxy-C 1-6 alkyl)ethynyl]guanine, 7-deaza-7-C 1-6 alkylguanine, 7-deaza-7-C 2-6 alkenylguanine, 7-deaza-7-C 2-6 alkynylguanine, or 7-deaza-7-halogenoguanine.

2. The antisense oligonucleic acid according to claim 1 , wherein the 2′,4′-non-bridged nucleic acid residue with the one or more modified bases is contained in a sequence of TGC or TCC.

3. The antisense oligonucleic acid according to claim 1 , wherein the 2′,4′-non-bridged nucleic acid residue is DNA.

4. The antisense oligonucleic acid according to claim 2 , wherein the 2′,4′-non-bridged nucleic acid residue is DNA.

5. The antisense oligonucleic acid according to claim 1 , wherein the 2′,4′-bridged nucleic acid residue has a structure of any of the following formulas (I) to (III):

wherein
X 1 is O, S, a >N(R 3 ) group, a —C(═O)—O— group or a —C(═O)—N(R 4 )— group (R 3 and R 4 are each independently H or a C 1-6 alkyl group),
X 2 is a guanidino group represented by any of the following formulas (IV) to (VII):

wherein R 5 -R 18 are each independently H, a C 1-6 alkyl group, a C 3-10 cycloalkyl group, an amino-protecting group or a 2-cyanoethyloxycarbonyl group,
X 3 is O, S, a >N(R 19 ) group, a —C(═O)—O— group or a —C(═O)—N(R 20 )— group (R 19 and R 20 are each independently H or a C 1-6 alkyl group),
Y 1 -Y 3 are each independently O − or S − ,
Base is a nucleic acid base group,
R 1 and R 2 are each independently H, a C 1-6 alkyl group or R 1 and R 2 may be taken together to form a C 1-4 alkylene group, and
n is an integer of not less than 0 and not more than 2.

6. The antisense oligonucleic acid according to claim 2 , wherein the 2′,4′-bridged nucleic acid residue has a structure of any of the following formulas (I) to (III):

wherein
X 1 is O, S, a >N(R 3 ) group, a —C(═O)—O— group or a —C(═O)—N(R 4 )— group (R 3 and R 4 are each independently H or a C 1-6 alkyl group),
X 2 is a guanidino group represented by any of the following formulas (IV) to (VII):

wherein R 5 -R 18 are each independently H, a C 1-6 alkyl group, a C 3-10 cycloalkyl group, an amino-protecting group or a 2-cyanoethyloxycarbonyl group,
X 3 is O, S, a >N(R 19 ) group, a —C(═O)—O— group or a —C(═O)—N(R 20 )— group (R 19 and R 20 are each independently H or a C 1-6 alkyl group),
Y 1 -Y 3 are each independently O − or S − ,
Base is a nucleic acid base group,
R 1 and R 2 are each independently H, a C 1-6 alkyl group or R 1 and R 2 may be taken together to form a C 1-4 alkylene group, and
n is an integer of not less than 0 and not more than 2.

7. The antisense oligonucleic acid according to claim 3 , wherein the 2′,4′-bridged nucleic acid residue has a structure of any of the following formulas (I) to (III):

wherein
X 1 is O, S, a >N(R 3 ) group, a —C(═O)—O— group or a —C(═O)—N(R 4 )— group (R 3 and R 4 are each independently H or a C 1-6 alkyl group),
X 2 is a guanidino group represented by any of the following formulas (IV) to (VII):

wherein R 5 -R 18 are each independently H, a C 1-6 alkyl group, a C 3-10 cycloalkyl group, an amino-protecting group or a 2-cyanoethyloxycarbonyl group,
X 3 is O, S, a >N(R 19 ) group, a —C(═O)—O— group or a —C(═O)—N(R 20 )— group (R 19 and R 20 are each independently H or a C 1-6 alkyl group),
Y 1 -Y 3 are each independently O − or S − ,
Base is a nucleic acid base group,
R 1 and R 2 are each independently H, a C 1-6 alkyl group or R 1 and R 2 may be taken together to form a C 1-4 alkylene group, and
n is an integer of not less than 0 and not more than 2.

8. The antisense oligonucleic acid according to claim 4 , wherein the 2′,4′-bridged nucleic acid residue has a structure of any of the following formulas (I) to (III):

wherein
X 1 is O, S, a >N(R 3 ) group, a —C(═O)—O— group or a —C(═O)—N(R 4 )— group (R 3 and R 4 are each independently H or a C 1-6 alkyl group),
X 2 is a guanidino group represented by any of the following formulas (IV) to (VII):

wherein R 5 -R 18 are each independently H, a C 1-6 alkyl group, a C 3-10 cycloalkyl group, an amino-protecting group or a 2-cyanoethyloxycarbonyl group,
X 3 is O, S, a >N(R 19 ) group, a —C(═O)—O— group or a —C(═O)—N(R 20 )— group (R 19 and R 20 are each independently H or a C 1-6 alkyl group),
Y 1 -Y 3 are each independently O − or S − ,
Base is a nucleic acid base group,
R 1 and R 2 are each independently H, a C 1-6 alkyl group or R 1 and R 2 may be taken together to form a C 1-4 alkylene group, and
n is an integer of not less than 0 and not more than 2.

9. The antisense oligonucleic acid according to claim 5 , wherein the 2′,4′-bridged nucleic acid residue has a structure of the formula (I), X 1 is O and n is 1.

10. The antisense oligonucleic acid according to claim 6 , wherein the 2′,4′-bridged nucleic acid residue has a structure of the formula (I), X 1 is O and n is 1.

11. The antisense oligonucleic acid according to claim 7 , wherein the 2′,4′-bridged nucleic acid residue has a structure of the formula (I), X 1 is O and n is 1.

12. The antisense oligonucleic acid according to claim 8 , wherein the 2′,4′-bridged nucleic acid residue has a structure of the formula (I), X 1 is O and n is 1.

13. The antisense oligonucleic acid according to claim 1 showing reduced hepatotoxicity compared to that before introduction of the modification into the base of the nucleic acid residue.

Assignees

• Univ Osaka

Inventors

• Obika Satoshi
• Waki Reiko
• Inoue Takao
• Yoshida Tokuyuki
• Morihiro Kunihiko
• Kasahara Yuya
• Mikami Atsushi

Classifications

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• A61K31/7115

  Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine · CPC title

• A61K31/712

  Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C12N2320/53

  reducing unwanted side-effects · CPC title